PMID- 29675798
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1869-6953 (Print)
IS  - 1869-6961 (Electronic)
IS  - 1869-6961 (Linking)
VI  - 9
IP  - 3
DP  - 2018 Jun
TI  - A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly 
      Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes 
      Previously Receiving 1-2 Oral Anti-Diabetic Drugs.
PG  - 1149-1167
LID - 10.1007/s13300-018-0424-2 [doi]
AB  - INTRODUCTION: Once-weekly semaglutide is a new glucagon-like peptide-1 (GLP-1) 
      analogue administered at a 1.0 or 0.5 mg dose. As head-to-head trials assessing 
      once-weekly semaglutide as an add-on to 1-2 oral anti-diabetic drugs (OADs) vs 
      other GLP-1 receptor agonists (GLP-1 RAs) are limited, a network meta-analysis 
      (NMA) was performed. The objective was to assess the relative efficacy and safety 
      of once-weekly semaglutide vs GLP-1 RAs in patients with type 2 diabetes (T2D) 
      inadequately controlled on 1-2 OADs. METHODS: A systematic literature review 
      (SLR) was conducted in order to identify trials of GLP-1 RAs in patients 
      inadequately controlled on 1-2 OADs. Data at 24 +/- 4 weeks were extracted for 
      efficacy and safety outcomes (feasible for analysis in a NMA), which included the 
      key outcomes of change from baseline in glycated hemoglobin (HbA(1c)), systolic 
      blood pressure (SBP), and weight, as well as discontinuation due to adverse 
      events (AEs). Data were synthesized using a NMA and a Bayesian framework. 
      RESULTS: In total, 26 studies were included across the base case analyses. 
      Once-weekly semaglutide 1.0 mg was associated with significantly greater 
      reductions in HbA(1c) and weight vs all GLP-1 RA comparators. Once-weekly 
      semaglutide 0.5 mg also achieved significantly greater reductions in HbA(1c) and 
      weight compared with the majority of other GLP-1 RAs. Both doses of once-weekly 
      semaglutide were associated with similar odds of discontinuation due to AEs 
      compared with other GLP-1 RAs. CONCLUSION: Overall, once-weekly semaglutide 
      1.0 mg as an add-on to 1-2 OADs is the most efficacious GLP-1 RA in terms of the 
      reduction of HbA(1c) and weight from baseline after 6 months of treatment. In 
      addition, the analysis suggests that once-weekly semaglutide is well tolerated 
      and not associated with an increase in discontinuations due to AEs compared with 
      other GLP-1 RAs. FUNDING: Novo Nordisk.
FAU - Witkowski, Michal
AU  - Witkowski M
AD  - DRG Abacus, Bicester, Oxfordshire, UK.
FAU - Wilkinson, Lars
AU  - Wilkinson L
AD  - Novo Nordisk A/S, Soborg, Denmark.
FAU - Webb, Neil
AU  - Webb N
AD  - DRG Abacus, Bicester, Oxfordshire, UK. nwebb@teamdrg.com.
FAU - Weids, Alan
AU  - Weids A
AD  - DRG Abacus, Bicester, Oxfordshire, UK.
FAU - Glah, Divina
AU  - Glah D
AD  - Novo Nordisk Ltd, Gatwick, UK.
FAU - Vrazic, Hrvoje
AU  - Vrazic H
AUID- ORCID: 0000-0001-8151-9899
AD  - Novo Nordisk A/S, Soborg, Denmark.
LA  - eng
PT  - Journal Article
DEP - 20180419
PL  - United States
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related 
      disorders
JID - 101539025
PMC - PMC5984927
OTO - NOTNLM
OT  - GLP-1 receptor agonist
OT  - Glycemic control
OT  - HbA1c
OT  - Network meta-analysis
OT  - Semaglutide
OT  - Systematic review
OT  - Systolic blood pressure
OT  - Type 2 diabetes
OT  - Weight
EDAT- 2018/04/21 06:00
MHDA- 2018/04/21 06:01
PMCR- 2018/04/19
CRDT- 2018/04/21 06:00
PHST- 2018/03/16 00:00 [received]
PHST- 2018/04/21 06:00 [pubmed]
PHST- 2018/04/21 06:01 [medline]
PHST- 2018/04/21 06:00 [entrez]
PHST- 2018/04/19 00:00 [pmc-release]
AID - 10.1007/s13300-018-0424-2 [pii]
AID - 424 [pii]
AID - 10.1007/s13300-018-0424-2 [doi]
PST - ppublish
SO  - Diabetes Ther. 2018 Jun;9(3):1149-1167. doi: 10.1007/s13300-018-0424-2. Epub 2018 
      Apr 19.